Skip to main content
  • PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial

    Trial results are last major clinical milestone prior to submission of regulatory market applications

    Learn More
  • The BioBuzz on... Profectus BioSciences, Inc.’s President Jeffrey N. Meshulam

    Profectus leader speaks on Ebola, IHV, and vaccine development

    Learn More
  • VisiSonics' RealSpace 3D Audio Software Licensed by Oculus for Virtual Reality

    Technology to be used in future VR Headset

    Learn More
  • Tokai Pharmaceuticals, Inc. Rings The Nasdaq Stock Market Opening Bell

    Tokai went public in September 2014. The company’s lead drug candidate, galeterone, is a highly selective, multi-targeted, oral small molecule drug candidate for the treatment of prostate cancer.

    Learn more
  • Baltimore Sun: Five questions with Bill Niland, Harpoon Medical CEO

    CEO discusses recent success and looking towards the future

    Learn More
  • Hot Technologies Available for Licensing

    UM Ventures is organized to move research outcomes into products and services, tools and diagnostics that will benefit society.

    Learn More

Receive Tech Alerts

Sign up to receive current new technology announcements and other UM Ventures news.

Select Your Interest(s)

Proudly showcasing UM Ventures Companies

In the last two years, UM Ventures has increased technology licenses by 46 percent (28 in FY11 vs. 41 in FY13) and new startup companies created by UM faculty increased by 120 percent (5 in FY11 to 11 in Fy13).

University of Maryland, College Park
University of Maryland, Baltimore

UM Ventures is a joint initiative of the University of Maryland, Baltimore and University of Maryland, College Park to commercialize technologies and expand industry collaboration.

Learn More